The new BIO chair is a big personality with an eye for coyotes
The next leader of biotech’s largest trade organization is an industry lifer with a fondness for going off-script and a farm occasionally troubled by roving canines.
Jeremy Levin, former CEO of Teva and current CEO of Ovid Therapeutics, is taking the reins as chair of BIO. Speaking to STAT’s Kate Sheridan at the group’s annual conference in Philadelphia, he outlined his goals for BIO, his personal politics, and the importance of protecting innocent livestock from predatory coyotes.
“As chairman, it gives me the opportunity at a time of absolutely critical moment, a time with huge change, to ask a couple of very important questions,” Levin said. Among them: How can the biotech industry make sure it’s inventing stuff patients need _and_ can access?
Read more.
Jeremy Levin, former CEO of Teva and current CEO of Ovid Therapeutics, is taking the reins as chair of BIO. Speaking to STAT’s Kate Sheridan at the group’s annual conference in Philadelphia, he outlined his goals for BIO, his personal politics, and the importance of protecting innocent livestock from predatory coyotes.
“As chairman, it gives me the opportunity at a time of absolutely critical moment, a time with huge change, to ask a couple of very important questions,” Levin said. Among them: How can the biotech industry make sure it’s inventing stuff patients need _and_ can access?
Read more.
No hay comentarios:
Publicar un comentario